Trident Lifeline (BOM:543616) has partnered with National Institutes of Pharmaceutical Education and Research, Ahmedabad, India, for the technology transfer of Vorinostat, a drug used in cancer treatment, according to an Indian bourse filing on Wednesday.
The company plans to scale up production and introduce it to the Indian market, aiming to improve access and affordability for patients, the filing said.
Trident Lifeline shares were up 5.8% in recent trading.
Price (INR): ₹283.75, Change: ₹+16, Percent Change: +5.82%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.